Drug reference

C1-esterase inhibitor

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 326

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Indications And Dose

BERINERT ® Acute attacks of hereditary angioedema (under expert supervision) ▶BY SLOW INTRAVENOUS INJECTION, OR BY INTRAVENOUS INFUSION ▶Adult: 20 units/kg Short-term prophylaxis of hereditary angioedema before dental, medical, or surgical procedures (under expert supervision) ▶BY SLOW INTRAVENOUS INJECTION, OR BY INTRAVENOUS INFUSION ▶Adult: 1000 units for 1 dose, to be administered less than 6 hours before procedure CINRYZE ® Acute attacks of hereditary angioedema (under expert supervision) ▶BY SLOW INTRAVENOUS INJECTION ▶Adult: 1000 units for 1 dose, dose may be repeated if necessary after 60 minutes (or sooner for patients experiencing laryngeal attacks or if treatment initiation is delayed) Short-term prophylaxis of hereditary angioedema before dental, medical, or surgical procedures (under expert supervision) ▶BY SLOW INTRAVENOUS INJECTION ▶Adult: 1000 units for 1 dose, to be administered up to 24 hours before procedure Long-term prophylaxis of severe, recurrent attacks of hereditary angioedema where acute treatment is inadequate, or when oral prophylaxis is inadequate or not tolerated (under expert supervision) ▶BY SLOW INTRAVENOUS INJECTION ▶Adult: 1000 units every 3–4 days, interval between doses to be adjusted according to response

PDF page 326

Cautions

Vaccination against hepatitis A and hepatitis B may be required

PDF page 326

Prescribing And Dispensing Information

C1-esterase inhibitor is prepared from human plasma.

PDF page 326

National Funding Access Decisions

CINRYZE ® All Wales Medicines Strategy Group (AWMSG) decisions The All Wales Medicines Strategy Group has advised (October 2017) that C1-esterase inhibitor (Cinryze ®) is recommended as an option for use within NHS Wales for the treatment and pre-procedure prevention of angioedema attacks in adults with hereditary angioedema (HAE); routine prevention of angioedema attacks in adults with severe and recurrent attacks of HAE, who are intolerant to or insufﬁciently protected by oral prevention treatments, or patients who are inadequately managed with repeated acute treatment.

PDF page 326

Safety

Side Effects

▶Rare or very rare Dizziness. dyspnoea. ﬂushing. headache . hypersensitivity. hypertension. hypotension. nausea. tachycardia. thrombosis (with high doses). urticaria

PDF page 326

Pregnancy

Manufacturer advises avoid unless essential.

PDF page 326

Dose and formulations

Medicinal Forms

There can be variation in the licensing of different medicines containing the same drug. Powder and solvent for solution for injection ELECTROLYTES: May contain Sodium ▶Berinert P (CSL Behring UK Ltd) C1-esterase inhibitor 500 unit Berinert 500unit powder and solvent for solution for injection vials | 1 vial P £550.00 DT = £550.00 C1-esterase inhibitor 1500 unit Berinert 1,500unit powder and solvent for solution for injection vials | 1 vial P £1,650.00 DT = £1,650.00 ▶Cinryze (Shire Pharmaceuticals Ltd) A C1-esterase inhibitor 500 unit Cinryze 500unit powder and solvent for solution for injection vials | 2 vial P £1,336.00

PDF page 326

Dose text by age group

Adult

20 units/kg

First-line fragment. Read the complete Indications and Dose section above.

PDF page 326

Adult

1000 units for 1 dose, to be administered less

First-line fragment. Read the complete Indications and Dose section above.

PDF page 326

Adult

1000 units for 1 dose, dose may be repeated if

First-line fragment. Read the complete Indications and Dose section above.

PDF page 326

Adult

1000 units for 1 dose, to be administered up to

First-line fragment. Read the complete Indications and Dose section above.

PDF page 326

Adult

1000 units every 3–4 days, interval between

First-line fragment. Read the complete Indications and Dose section above.

PDF page 326

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.

Drug reference

C1-esterase inhibitor

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 326

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Indications And Dose

PDF page 326

Cautions

Vaccination against hepatitis A and hepatitis B may be required

PDF page 326

Prescribing And Dispensing Information

C1-esterase inhibitor is prepared from human plasma.

PDF page 326

National Funding Access Decisions

PDF page 326

Safety

Side Effects

▶Rare or very rare Dizziness. dyspnoea. ﬂushing. headache . hypersensitivity. hypertension. hypotension. nausea. tachycardia. thrombosis (with high doses). urticaria

PDF page 326

Pregnancy

Manufacturer advises avoid unless essential.

PDF page 326

Dose and formulations

Medicinal Forms

PDF page 326

Dose text by age group

Adult

20 units/kg

First-line fragment. Read the complete Indications and Dose section above.

PDF page 326

Adult

1000 units for 1 dose, to be administered less

First-line fragment. Read the complete Indications and Dose section above.

PDF page 326

Adult

1000 units for 1 dose, dose may be repeated if

First-line fragment. Read the complete Indications and Dose section above.

PDF page 326

Adult

1000 units for 1 dose, to be administered up to

First-line fragment. Read the complete Indications and Dose section above.

PDF page 326

Adult

1000 units every 3–4 days, interval between

First-line fragment. Read the complete Indications and Dose section above.

PDF page 326

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.